{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T02:08:26Z","timestamp":1783822106011,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40261-026-01567-7","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:01:05Z","timestamp":1780718465000},"page":"869-881","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the Impact on Health and Productivity Outcomes of Anti-PD-(L)1 Agents to Treat Early-Stage Cancers in Italy"],"prefix":"10.1007","volume":"46","author":[{"given":"Andrea","family":"Marcellusi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isobel","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Zhi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Catanzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Ascone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Calandriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Aguiar-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"1567_CR1","unstructured":"Manzano ASC, Hofmarcher T, Wilking N. Comparator report on cancer in Europe 2025\u2014disease burden, costs and access to medicines and molecular diagnostics. 2025. https:\/\/www.efpia.eu\/media\/nbbbsbhp\/ihe-comparator-report-on-cancer-in-europe-2025.pdf."},{"key":"1567_CR2","unstructured":"Associazione Italiana Registri Tumori (AIRTUM). I numeri del cancro in Italia 2023. 2023. https:\/\/www.registri-tumori.it\/cms\/sites\/default\/files\/pubblicazioni\/I%20numeri%20del%20cancro%20in%20Italia%20-%20versione%20per%20operatori_1.pdf."},{"key":"1567_CR3","volume-title":"EU country cancer profile: Italy 2025","author":"OECD\/European Commission","year":"2025","unstructured":"OECD\/European Commission. EU country cancer profile: Italy 2025. Paris: OECD Publishing; 2025."},{"issue":"10512","key":"1567_CR4","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(25)01635-6","volume":"406","author":"LM Force","year":"2025","unstructured":"Force LM, Kocarnik JM, May ML, Bhangdia K, Crist A, Penberthy L, et al. The global, regional, and national burden of cancer, 1990\u20132023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10512):1565\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(25)01635-6.","journal-title":"Lancet"},{"key":"1567_CR5","unstructured":"A A. Tumori: spesi 20 miliardi nel 2022 per le cure, un quarto a carico dei pazienti. Il Sole 24 ORE 2023. https:\/\/www.ilsole24ore.com\/art\/tumori-spesi-20-miliardi-2022-le-cure-quarto-carico-pazienti-AFJWBK4B."},{"key":"1567_CR6","unstructured":"Ministero della Salute. Piano Oncologico Nazionale: documento di pianificazione e indirizzo per la prevenzione e il contrasto del cancro 2023-2027. 2023. https:\/\/www.salute.gov.it\/new\/sites\/default\/files\/imported\/C_17_pubblicazioni_3291_allegato.pdf."},{"issue":"6586","key":"1567_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay9040","volume":"375","author":"D Crosby","year":"2022","unstructured":"Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, et al. Early detection of cancer. Science. 2022;375(6586):eaay9040. https:\/\/doi.org\/10.1126\/science.aay9040.","journal-title":"Science"},{"issue":"3","key":"1567_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244\u201358. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.012.","journal-title":"Ann Oncol"},{"issue":"1","key":"1567_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","volume":"36","author":"T Amaral","year":"2025","unstructured":"Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, et al. Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(1):10\u201330. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.006.","journal-title":"Ann Oncol"},{"key":"1567_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.003","author":"A Zer","year":"2025","unstructured":"Zer A, Ahn MJ, Barlesi F, Bubendorf L, De Ruysscher D, Garrido P, et al. Early and locally advanced non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.003.","journal-title":"Ann Oncol"},{"issue":"9","key":"1567_CR11","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","volume":"33","author":"A Oaknin","year":"2022","unstructured":"Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, et al. Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860\u201377. https:\/\/doi.org\/10.1016\/j.annonc.2022.05.009.","journal-title":"Ann Oncol"},{"issue":"10336","key":"1567_CR12","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected Stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(22)00562-1.","journal-title":"Lancet"},{"issue":"11","key":"1567_CR13","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","volume":"29","author":"JM Kirkwood","year":"2023","unstructured":"Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, et al. Adjuvant nivolumab in resected Stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023;29(11):2835\u201343. https:\/\/doi.org\/10.1038\/s41591-023-02583-2.","journal-title":"Nat Med"},{"issue":"5","key":"1567_CR14","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/s1470-2045(21)00065-6","volume":"22","author":"AMM Eggermont","year":"2021","unstructured":"Eggermont AMM, Blank CU, Mandal\u00e0 M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected Stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):643\u201354. https:\/\/doi.org\/10.1016\/s1470-2045(21)00065-6.","journal-title":"Lancet Oncol"},{"issue":"19","key":"1567_CR15","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected Stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1709030.","journal-title":"N Engl J Med"},{"issue":"8","key":"1567_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang Y-H, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385(8):683\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2106391.","journal-title":"N Engl J Med"},{"issue":"21","key":"1567_CR17","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391(21):1981\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2409932.","journal-title":"N Engl J Med"},{"key":"1567_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2239","volume":"31","author":"N Harbeck","year":"2020","unstructured":"Harbeck N, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. LBA11 IMpassion031: results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC). Ann Oncol. 2020;31:S1144. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2239.","journal-title":"Ann Oncol"},{"issue":"10459","key":"1567_CR19","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","volume":"404","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404(10459):1240\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(24)01756-2.","journal-title":"Lancet"},{"issue":"10308","key":"1567_CR20","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/s0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C, Cs\u0151szi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected Stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344\u201357. https:\/\/doi.org\/10.1016\/s0140-6736(21)02098-5.","journal-title":"Lancet"},{"issue":"2","key":"1567_CR21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cas.16030","volume":"115","author":"T Mitsudomi","year":"2024","unstructured":"Mitsudomi T, Ito H, Okada M, Sugawara S, Shio Y, Tomii K, et al. Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816. Cancer Sci. 2024;115(2):540\u201354. https:\/\/doi.org\/10.1111\/cas.16030.","journal-title":"Cancer Sci"},{"issue":"18","key":"1567_CR22","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389(18):1672\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2304875.","journal-title":"N Engl J Med"},{"key":"1567_CR23","unstructured":"Agenzia Italiana del Farmaco (AIFA). Regime di rimborsabilita\u2019 e prezzo a seguito di nuove indicazioni terapeutiche del medicinale per uso umano \u00abKeytruda\u00bb. (Determina n. 240\/2025). 2025. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2025-03-03&atto.codiceRedazionale=25A01307."},{"key":"1567_CR24","unstructured":"Agenzia Italiana del Farmaco (AIFA). Regime di rimborsabilita\u2019 e prezzo a seguito di nuove indicazioni terapeutiche del medicinale per uso umano \u00abKeytruda\u00bb. (Determina n. 1762\/2019). 2019. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2019\/12\/10\/19A07733\/sg."},{"key":"1567_CR25","unstructured":"Agenzia Italiana del Farmaco (AIFA). Regime di rimborsabilita\u2019 e prezzo, a seguito di nuove indicazioni terapeutiche, del medicinale per uso umano \u00abKeytruda\u00bb. (Determina n. 476\/2023). 2023. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2023-07-18&atto.codiceRedazionale=23A04031."},{"key":"1567_CR26","unstructured":"Agenzia Italiana del Farmaco (AIFA). Regime di rimborsabilita\u2019 e prezzo, a seguito di nuove indicazioni terapeutiche, del medicinale per uso umano \u00abOpdivo\u00bb. (Determina n. 267\/2025). 2025. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2025\/03\/24\/25A01679\/SG."},{"issue":"1","key":"1567_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12282-023-01514-w","volume":"31","author":"M Williamson","year":"2024","unstructured":"Williamson M, Press DJ, Hansen SA, Tomar A, Jhuti GS, Revil C, et al. Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy. Breast Cancer. 2024;31(1):84\u201395. https:\/\/doi.org\/10.1007\/s12282-023-01514-w.","journal-title":"Breast Cancer"},{"key":"1567_CR28","unstructured":"Agenzia Italiana del Farmaco (AIFA). Linee guida per la compilazione del dossier a supporto della domanda di rimborsabilit\u00e0 e prezzo di un medicinale. 2019. https:\/\/www.aifa.gov.it\/documents\/20142\/1283800\/Linee_guida_dossier_domanda_rimborsabilita.pdf\/8249e3d6-b2fc-915d-a211-02abafb8aa6d."},{"issue":"7","key":"1567_CR29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40261-020-00922-6","volume":"40","author":"AG Bensimon","year":"2020","unstructured":"Bensimon AG, Zhou Z-Y, Jenkins M, Song Y, Gao W, Signorovitch J, et al. An economic evaluation of pembrolizumab versus other adjuvant treatment strategies for resected high-risk Stage III melanoma in the USA. Clin Drug Investig. 2020;40(7):629\u201343. https:\/\/doi.org\/10.1007\/s40261-020-00922-6.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"1567_CR30","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s12325-022-02365-1","volume":"40","author":"M Huang","year":"2023","unstructured":"Huang M, Fasching AP, Haiderali A, Xue W, Yang C, Pan W, et al. Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab for high-risk early-stage triple-negative breast cancer in the United States. Adv Ther. 2023;40(3):1153\u201370. https:\/\/doi.org\/10.1007\/s12325-022-02365-1.","journal-title":"Adv Ther"},{"issue":"5","key":"1567_CR31","doi-asserted-by":"publisher","first-page":"612.e1","DOI":"10.1016\/j.clgc.2023.03.016","volume":"21","author":"Y Lai","year":"2023","unstructured":"Lai Y, Bensimon AG, Gao E, Bhattacharya R, Xu R, Chevure J, et al. Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of renal cell carcinoma post-nephrectomy in the United States. Clin Genitourin Cancer. 2023;21(5):612.e1-.e11. https:\/\/doi.org\/10.1016\/j.clgc.2023.03.016.","journal-title":"Clin Genitourin Cancer"},{"key":"1567_CR32","unstructured":"National Institute for Health and Care Excellence. TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma. 2022 [cited 12 August 2025]. https:\/\/www.nice.org.uk\/guidance\/ta837."},{"key":"1567_CR33","unstructured":"National Institute for Health and Care Excellence. TA766: Pembrolizumab for adjuvant treatment of completely resected Stage 3 melanoma. 2022 [cited 12 August 2025]. https:\/\/www.nice.org.uk\/guidance\/ta766."},{"key":"1567_CR34","unstructured":"National Institute for Health and Care Excellence. TA830: Pembrolizumab for adjuvant treatment of renal cell carcinoma. 2022 [cited 12 August 2025]. https:\/\/www.nice.org.uk\/guidance\/ta830."},{"key":"1567_CR35","unstructured":"National Institute for Health and Care Excellence. TA851: pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer. 2022 [cited 12 August 2025]. https:\/\/www.nice.org.uk\/guidance\/ta851."},{"key":"1567_CR36","unstructured":"National Institute for Health and Care Excellence. TA1017: pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. 2024 [cited 12 August 2025]. https:\/\/www.nice.org.uk\/guidance\/ta1017\/evidence\/committee-papers-pdf-13604993245."},{"issue":"7","key":"1567_CR37","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1007\/s12325-023-02525-x","volume":"40","author":"S Zhang","year":"2023","unstructured":"Zhang S, Bensimon AG, Xu R, Jiang R, Greatsinger A, Zhang A, et al. Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of resected Stage IIB or IIC melanoma in the United States. Adv Ther. 2023;40(7):3038\u201355. https:\/\/doi.org\/10.1007\/s12325-023-02525-x.","journal-title":"Adv Ther"},{"key":"1567_CR38","unstructured":"Fan H, Feng H, Gridelli C, Rai P, Riccaboni M. Cost-effectiveness of perioperative pembrolizumab for resectable nsclc: a lifetime evaluation in the Italian healthcare system SIFO Congress; 2025."},{"key":"1567_CR39","first-page":"85","volume":"19","author":"S Silvola","year":"2024","unstructured":"Silvola S, Restelli U, Croce D, Lai Y, Iacovelli R. Analisi di costo-utilit\u00e0 dell\u2019utilizzo di pembrolizumab per il trattamento adiuvante del carcinoma delle cellule renali post nefrectomia nel contesto italiano. Clinicoecon Outcomes Res. 2024;19:85\u201398.","journal-title":"Clinicoecon Outcomes Res"},{"key":"1567_CR40","unstructured":"Valentini I, Basile M, Rumi F, Di Brino E, Haideral A, Jamotte A. Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy in the treatment of high-risk triple-negative breast cancer: evidence from DALY indicator integration ISPOR Rome Chapter 2025; 2025."},{"key":"1567_CR41","unstructured":"Associazione Italiana di Oncologia Medica (AIOM). I numeri del cancro in Italia 2022. 2022. https:\/\/www.aiom.it\/wp-content\/uploads\/2022\/12\/2022_AIOM_NDC-web.pdf."},{"issue":"5","key":"1567_CR42","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989x12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices \u2013 overview: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012;32(5):667\u201377. https:\/\/doi.org\/10.1177\/0272989x12454577.","journal-title":"Med Decis Making"},{"key":"1567_CR43","unstructured":"Statbel. Tables de mortalit\u00e9 et esp\u00e9rance de vie. 2022. https:\/\/statbel.fgov.be\/fr\/themes\/population\/mortalite-et-esperance-de-vie\/tables-de-mortalite-et-esperance-de-vie#documents."},{"issue":"1","key":"1567_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/21556660.2019.1649266","volume":"8","author":"M Lorenzi","year":"2019","unstructured":"Lorenzi M, Arndorfer S, Aguiar-Iba\u00f1ez R, Scherrer E, Liu FX, Krepler C. An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of Stage III melanoma. J Drug Assess. 2019;8(1):135\u201345. https:\/\/doi.org\/10.1080\/21556660.2019.1649266.","journal-title":"J Drug Assess"},{"key":"1567_CR45","unstructured":"MSD. KEYNOTE-671 neoadjuvant\/adjuvant NSCLC: SLR and NMA. 2024."},{"issue":"5","key":"1567_CR46","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509\u201318. https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00700.x.","journal-title":"Value Health"},{"issue":"3","key":"1567_CR47","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/14796694.2024.2436342","volume":"21","author":"R Aguiar-Ib\u00e1\u00f1ez","year":"2025","unstructured":"Aguiar-Ib\u00e1\u00f1ez R, McQuarrie K, Jayade S, Penton H, DiGiovanni L, Raina R, et al. Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey. Future Oncol. 2025;21(3):349\u201365. https:\/\/doi.org\/10.1080\/14796694.2024.2436342.","journal-title":"Future Oncol"},{"key":"1567_CR48","unstructured":"OECD. Average usual weekly hours worked on the main job. 2025. https:\/\/data-explorer.oecd.org\/vis?tm=working%20hours%20per%20week&pg=0&snb=16&vw=tb&df[ds]=dsDisseminateFinalDMZ&df[id]=DSD_HW%40DF_AVG_USL_WK_WKD&df[ag]=OECD.ELS.SAE&df[vs]=1.0&dq=ITA..._T._T....ICSE93_1._T...&pd=2010%2C&to[TIME_PERIOD]=false."},{"key":"1567_CR49","unstructured":"ISTAT. Gross hourly wage per hour paid of employee jobs in euros (median). 2025 [cited 25 July 2025]. https:\/\/esploradati.istat.it\/databrowser\/#\/en\/dw\/categories\/IT1,Z0500LAB,1.0\/LAB_EMPLWAGE\/DCSC_RACLI\/IT1,533_957_DF_DCSC_RACLI_1,1.0."},{"key":"1567_CR50","unstructured":"Istituto Nazionale di Statistica. Occupati e disoccupati (dati provvisori) \u2013 Febbraio 2026. 2026 [cited 01 April 2026]. https:\/\/www.istat.it\/comunicato-stampa\/occupati-e-disoccupati-dati-provvisori-febbraio-2026\/."},{"issue":"10440","key":"1567_CR51","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/s0140-6736(24)00757-8","volume":"403","author":"GBD 2021 Diseases and Injuries Collaborators","year":"2024","unstructured":"GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(24)00757-8.","journal-title":"Lancet"},{"key":"1567_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-025-00357-z","author":"A Bento-Abreu","year":"2025","unstructured":"Bento-Abreu A, Vandekeere S, S\u00f6nmez D, Neves C, Mantaian T, Ethgen O, et al. The health impact of using anti-PD-1 agents to treat early-stage cancer in Belgium. Oncol Ther. 2025. https:\/\/doi.org\/10.1007\/s40487-025-00357-z.","journal-title":"Oncol Ther"},{"key":"1567_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1601377","volume":"16","author":"A Favre-Bulle","year":"2025","unstructured":"Favre-Bulle A, Stankovic M, Mantaian T, Frei C, Schaefer S, Gabriel SS, et al. Health impact of using anti-PD-(L)1 agents to treat early-stage cancers in Switzerland: a modeling study. Front Immunol. 2025;16:1601377. https:\/\/doi.org\/10.3389\/fimmu.2025.1601377.","journal-title":"Front Immunol"},{"key":"1567_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1613120","volume":"16","author":"H Burton","year":"2025","unstructured":"Burton H, Greenall S, Tan YZ, Neves C, Macdonald N, Aguiar-Ib\u00e1\u00f1ez R. Impact on health outcomes and productive work of adding anti-PD-1 agents to treat early-stage cancers in the United Kingdom: a modelling study. Front Pharmacol. 2025;16:1613120. https:\/\/doi.org\/10.3389\/fphar.2025.1613120.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1567_CR55","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40258-023-00824-6","volume":"21","author":"M Ortega-Ortega","year":"2023","unstructured":"Ortega-Ortega M, Hanly P, Pearce A, Soerjomataram I, Sharp L. Projected impact on labour productivity costs of cancer-related premature mortality in Europe 2018-2040. Appl Health Econ Health Policy. 2023;21(6):877\u201389. https:\/\/doi.org\/10.1007\/s40258-023-00824-6.","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"1567_CR56","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/14737167.2025.2493130","volume":"25","author":"B Canali","year":"2025","unstructured":"Canali B, Apolone G, Ascierto PA, De Braud F, Grossi F, Perrone F, et al. Effect of immuno-oncology on clinical and economic outcomes for a selection of cancers in Italy. Expert Rev Pharmacoecon Outcomes Res. 2025;25(6):905\u201315. https:\/\/doi.org\/10.1080\/14737167.2025.2493130.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"1567_CR57","doi-asserted-by":"publisher","first-page":"8910","DOI":"10.18632\/oncotarget.13315","volume":"8","author":"R Costa","year":"2017","unstructured":"Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, et al. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget. 2017;8(5):8910\u201320. https:\/\/doi.org\/10.18632\/oncotarget.13315.","journal-title":"Oncotarget"},{"issue":"7","key":"1567_CR58","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","volume":"36","author":"E Felip","year":"2025","unstructured":"Felip E, Rojas CI, Schenker M, Kowalski DM, Casarini IA, Cs\u00f6szi T, et al. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Ann Oncol. 2025;36(7):775\u201385. https:\/\/doi.org\/10.1016\/j.annonc.2025.03.012.","journal-title":"Ann Oncol"},{"issue":"4","key":"1567_CR59","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4103\/ijpc.Ijpc_82_17","volume":"23","author":"MG Nayak","year":"2017","unstructured":"Nayak MG, George A, Vidyasagar MS, Mathew S, Nayak S, Nayak BS, et al. Quality of life among cancer patients. Indian J Palliat Care. 2017;23(4):445\u201350. https:\/\/doi.org\/10.4103\/ijpc.Ijpc_82_17.","journal-title":"Indian J Palliat Care"},{"key":"1567_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20021570","author":"MD Guerra-Mart\u00edn","year":"2023","unstructured":"Guerra-Mart\u00edn MD, Casado-Espinosa MDR, Gavira-L\u00f3pez Y, Holgado-Castro C, L\u00f3pez-Latorre I, Borrallo-Riego \u00c1. Quality of life in caregivers of cancer patients: a literature review. Int J Environ Res Public Health. 2023. https:\/\/doi.org\/10.3390\/ijerph20021570.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"1567_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12612-z","volume":"24","author":"KC Chung","year":"2024","unstructured":"Chung KC, Muthutantri A, Goldsmith GG, Watts MR, Brown AE, Patrick DL. Symptom impact and health-related quality of life (HRQoL) assessment by cancer stage: a narrative literature review. BMC Cancer. 2024;24(1):884. https:\/\/doi.org\/10.1186\/s12885-024-12612-z.","journal-title":"BMC Cancer"},{"issue":"2","key":"1567_CR62","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40487-025-00328-4","volume":"13","author":"R Aguiar-Ibanez","year":"2025","unstructured":"Aguiar-Ibanez R, McQuarrie K, Martinez A, Penton H, DiGiovanni L, Raina R, et al. A US survey across seven early-stage cancers assessing the humanistic burden of recurrence on patients and caregivers. Oncol Ther. 2025;13(2):339\u201361. https:\/\/doi.org\/10.1007\/s40487-025-00328-4.","journal-title":"Oncol Ther"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01567-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01567-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01567-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T02:02:34Z","timestamp":1783821754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01567-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":62,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1567"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01567-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrea Marcellusi has received honoraria as a speaker and adviser for MSD, Astra Zeneca, Eli Lilly and other pharma companies. He is an Editorial Board member of\n                      Clinical Drug Investigation\n                      , but was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Fabio Calabr\u00f2 has received honoraria as speaker for MSD, Astra Zeneca, Pfizer, Novartis, Bayer, Ipsen, Johnson and Johnson, Recordati and Astellas. Anna Maria Di Giacomo has served as an advisor or board member for MSD, Bristol Myers Squibb, Incyte, Pierre Fabre, Sanofi, GSK, Novartis, SunPharma and Immunocore. She has also received honoraria for MSD, Roche, Bristol Myers Squibb, Sanofi, Pierre Fabre, GSP and Vyvamed. Fabio Puglisi has received honoraria for advisory boards, activities as a speaker, travel grants and research grants from Amgen, Astra Zeneca, Bayer, Daiichi Sankyo, Celgene, Eisai, Eli Lilly, Exact Sciences, Gilead, Ipsen, Italfarmaco, Menarini, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Seagen, Takeda and Viatris. He has also received research funding from Astra Zeneca, Eisai and Roche. Alessio Cortellini received grants for consultancies\/advisory boards: MSD, OncoC4, Roche, Regeneron, Bristol Myers Squibb, Amgen, Daiichi Sankyo, Astra Zeneca, Access Infinity, Ardelis Health, Alpha Sight, Capvision, Techspert, Alira Health, Atheneum, Lightening Health. He also received speaker fees from Astra Zeneca, Roche, Pierre-Fabre, MSD, Sanofi\/Regeneron and Yuhan corporation, compensation for writing\/editorial activity from Bristol Myers Squibb, MSD and travel support from Sanofi, MSD, Roche and funding (to institution) from the International Association for the Study of Lung Cancer. Isobel Thornton, Yan Zhi Tan, Alessandro Catanzaro and Catarina Neves are employees of Lumanity, which have been contracted by MSD for this study, and do not have any further financial or nonfinancial interests to disclose. Fabrizio Ascone, Matilde Franceschini and Mario Calandriello are employees of MSD, Italy. Raquel Aguiar-Ib\u00e1\u00f1ez is an employee of Merck Canada Inc., Kirkland, QC, Canada. Yizhen Lai is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data used in this study can be made available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable; no coding was used for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All data used in this study were fully de-identified; ethics approval was not required and was not sought.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable; this modelling study is exempt from informed consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publication"}},{"value":"Study conceptualisation and design: all authors; study conduct: I.T., Y.Z.T., A.C., C.N. and Y.L.; analysis and interpretation of results: I.T., Y.Z.T., C.N. and Y.L.; draft manuscript preparation: I.T., Y.Z.T., C.N., R.A., M.F. and Y.L. All authors read and approved the final version and agree to be accountable for the research.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}